TY - JOUR
T1 - Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction
AU - Matsumoto, Sen
AU - Nakatani, Daisaku
AU - Sakata, Yasuhiko
AU - Suna, Shinichiro
AU - Shimizu, Masahiko
AU - Usami, Masaya
AU - Hara, Masahiko
AU - Sumitsuji, Satoru
AU - Nanto, Shinsuke
AU - Sasaki, Tatsuya
AU - Hamasaki, Toshimitsu
AU - Sato, Hiroshi
AU - Hori, Masatsugu
AU - Komuro, Issei
PY - 2013
Y1 - 2013
N2 - Background: Little is known about the prognostic significance of elevated serum heart-type fatty acid-binding protein (H-FABP) in post-acute myocardial infarction (post-AMI) patients. Methods and Results: A total of 1,283 post-AMI patients with available serum samples collected in the convalescent stage were studied. During a median follow-up period of 1,785 days, 176 patients (14%) had adverse events (all-cause mortality, n=81; non-fatal MI, n=44; readmission for heart failure [HF], n=51). Patients were divided into 2 groups according to a serum H-FABP level of 6.08 ng/ml, which was determined to be the optimal cut-off for discriminating all-cause mortality based on the maximum value of the area under the receiver operating characteristic curve. Patients with elevated H-FABP (>6.08 ng/ml, n=224) had a significantly higher incidence of death (18.3% vs. 3.8%, P<0.001) and readmission for HF (10.3% vs. 2.6%, P<0.001), but not of non-fatal MI (4.5% vs. 3.2%, P=0.187), compared to those with H-FABP <6.08 ng/ml. Multivariate Cox regression analysis indicated that elevated serum H-FABP was associated with an increased risk of mortality (hazard ratio [HR], 1.91; 95% confidence interval [CI]: 1.03-3.51, P=0.039) and readmission for HF (HR, 2.49; 95% CI: 1.15-5.39, P=0.020). Conclusions: Elevated serum H-FABP during the convalescent stage of AMI predicted long-term mortality and readmission for HF after survival discharge in the post-AMI patients.
AB - Background: Little is known about the prognostic significance of elevated serum heart-type fatty acid-binding protein (H-FABP) in post-acute myocardial infarction (post-AMI) patients. Methods and Results: A total of 1,283 post-AMI patients with available serum samples collected in the convalescent stage were studied. During a median follow-up period of 1,785 days, 176 patients (14%) had adverse events (all-cause mortality, n=81; non-fatal MI, n=44; readmission for heart failure [HF], n=51). Patients were divided into 2 groups according to a serum H-FABP level of 6.08 ng/ml, which was determined to be the optimal cut-off for discriminating all-cause mortality based on the maximum value of the area under the receiver operating characteristic curve. Patients with elevated H-FABP (>6.08 ng/ml, n=224) had a significantly higher incidence of death (18.3% vs. 3.8%, P<0.001) and readmission for HF (10.3% vs. 2.6%, P<0.001), but not of non-fatal MI (4.5% vs. 3.2%, P=0.187), compared to those with H-FABP <6.08 ng/ml. Multivariate Cox regression analysis indicated that elevated serum H-FABP was associated with an increased risk of mortality (hazard ratio [HR], 1.91; 95% confidence interval [CI]: 1.03-3.51, P=0.039) and readmission for HF (HR, 2.49; 95% CI: 1.15-5.39, P=0.020). Conclusions: Elevated serum H-FABP during the convalescent stage of AMI predicted long-term mortality and readmission for HF after survival discharge in the post-AMI patients.
KW - Acute myocardial infarction
KW - Cardiac event
KW - Heart-type fatty acid-binding protein
UR - http://www.scopus.com/inward/record.url?scp=84875488498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875488498&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-12-0999
DO - 10.1253/circj.CJ-12-0999
M3 - Article
C2 - 23291993
AN - SCOPUS:84875488498
VL - 77
SP - 1026
EP - 1032
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 4
ER -